<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833753</url>
  </required_header>
  <id_info>
    <org_study_id>H00008477</org_study_id>
    <nct_id>NCT02833753</nct_id>
  </id_info>
  <brief_title>Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI</brief_title>
  <official_title>Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I dose escalation study to determine how much chemotherapy can be safely
      administered into the abdomen while experiencing the fewest possible side effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two common combinations of chemotherapy drugs used to treat cancer of the colon,
      rectum, or appendix that has spread to the abdomen. One uses 5-fluorouracil (also called
      5-FU), leucovorin and oxaliplatin, and is called FOLFOX. The other uses 5-FU, leucovorin, and
      irinotecan, and is called FOLFIRI. The Food and Drug Administration (FDA) has approved each
      of these combinations as treatment for colon or rectal cancer. Each is given through the
      veins.

      FOLFOX and FOLFIRI do not work well for tumors growing in the abdominal cavity. The
      investigators are trying to determine if giving chemotherapy called oxaliplatin directly into
      the abdominal cavity will have a greater effect on the cancer.

      The FDA has approved oxaliplatin to be given to people through their veins to treat advanced
      colorectal cancer. Giving oxaliplatin directly into the abdomen in this study is experimental
      and is not approved by the FDA. This study will give the standard chemotherapy FOLFIRI
      through the veins and oxaliplatin directly into the abdomen. This is the first time
      intraperitoneal oxaliplatin is being given in combination with FOLFIRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are three cohorts of patients:
Group #1 is at 25mg/m2 of IP oxaliplatin and has been completed. Group #2 is at 55mg/m2 of IP oxaliplatin and is near completing. Group #3 is at 85mg/m2 of IP oxaliplatin and we haven't started enrolling yet.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define the maximum tolerated dose (MTD) of intraperitoneal (IP) oxaliplatin given with systemic FOLFIRI in patients with peritoneal carcinomatosis (PC) of colorectal or appendiceal origin</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Appendix Cancer</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.
The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients with receive dose level 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.
Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy</description>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must be 18 years of age or older and capable of providing informed consent
             indicating awareness of the investigational nature of this trial, in keeping with
             institutional policy

          -  Patients must be willing to return for follow-up

          -  The patient must consent to participate in the trial and must have signed an approved
             informed consent form conforming to institutional policy

          -  The patient must have histopathologically or cytologically confirmed colon, rectal or
             appendiceal adenocarcinoma with synchronous or metachronous peritoneal dissemination
             of disease.(Stage IV peritoneal based disease only)

          -  The patient must have active measurable disease by either abdominal computerized axial
             tomography (CT)/ Magnetic resonance imaging (MRI) or laparoscopy.

        At the time of enrollment, the patient must have: (within 14 days of enrollment)

          -  Absolute neutrophil count (ANC) &gt; 1200/mm3 and platelet count &gt; 140,000/mm3

          -  An international normalized ratio (INR) ≤ 1.5 (patients who are therapeutically
             anticoagulated for non-related medical conditions such as atrial fibrillation and
             whose anti- thrombotic treatment can be withheld for operation will be eligible)

          -  Adequate hepatic function must be met as evidenced by total serum bilirubin ≤ 1.5
             mg/dl (patients with total bilirubin &gt;1.5 mg/dL eligible only with Gilbert's
             syndrome); alkaline phosphatase &lt; 2.5 times the upper limit of normal; and, aspartate
             aminotransferase (AST) less than 1.5 times upper limit of normal [alkaline phosphatase
             and AST cannot both exceed the upper limit of normal]

          -  Serum renal functional parameters, blood urea nitrogen (BUN) and creatinine are within
             normal limits (estimated glomerular filtration rate (eGFR) &gt;50)

          -  Prior to enrollment the patient must have had a complete history and physical
             examination, electrocardiogram, within three months of enrollment

          -  Satisfactory cardiopulmonary function (as determined by Physician)

          -  Patients can have received prior systemic chemotherapy, radiation or surgery

          -  Patients must be able to undergo placement of an intraperitoneal (IP) catheter and a
             Port-A Cath, if not already present

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             2 or less

          -  Women of reproductive age and men who are sexually active must be willing to practice
             effective contraception

          -  Patients will be allowed to have secondary malignancies as long as they do not require
             active concomitant treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradley Switzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bradley Switzer, MD</last_name>
    <phone>774-442-3716</phone>
    <email>bradley.switzer@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Lambert, MD</last_name>
    <phone>508-334-5274</phone>
    <email>laura.lambert@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UMass Memorial Medical Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Switzer</last_name>
      <phone>774-442-3716</phone>
      <email>bradley.switzer@umassmemorial.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics</url>
    <description>Colon Cancer 2014</description>
  </link>
  <link>
    <url>http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index</url>
    <description>Cancer Facts and Figures 2015</description>
  </link>
  <reference>
    <citation>Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6.</citation>
    <PMID>17470860</PMID>
  </reference>
  <reference>
    <citation>Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.</citation>
    <PMID>25337750</PMID>
  </reference>
  <reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </reference>
  <reference>
    <citation>Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009 Feb 10;27(5):681-5. doi: 10.1200/JCO.2008.19.7160. Epub 2008 Dec 22.</citation>
    <PMID>19103728</PMID>
  </reference>
  <reference>
    <citation>Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000 Jan 15;88(2):358-63.</citation>
    <PMID>10640968</PMID>
  </reference>
  <reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </reference>
  <reference>
    <citation>Fajardo AD, Tan B, Reddy R, Fleshman J. Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis. Dis Colon Rectum. 2012 Oct;55(10):1044-52. doi: 10.1097/DCR.0b013e318265ad42.</citation>
    <PMID>22965403</PMID>
  </reference>
  <reference>
    <citation>Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002 Feb;13(2):267-72.</citation>
    <PMID>11886004</PMID>
  </reference>
  <reference>
    <citation>Elias D, Matsuhisa T, Sideris L, Liberale G, Drouard-Troalen L, Raynard B, Pocard M, Puizillou JM, Billard V, Bourget P, Ducreux M. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance. Ann Oncol. 2004 Oct;15(10):1558-65.</citation>
    <PMID>15367418</PMID>
  </reference>
  <reference>
    <citation>Gervais MK, Dubé P, McConnell Y, Drolet P, Mitchell A, Sideris L. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer. J Surg Oncol. 2013 Dec;108(7):438-43. doi: 10.1002/jso.23431. Epub 2013 Sep 9.</citation>
    <PMID>24018983</PMID>
  </reference>
  <reference>
    <citation>Ceelen W, De Somer F, Van Nieuwenhove Y, Vande Putte D, Pattyn P. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin. Eur J Surg Oncol. 2013 Jul;39(7):754-9. doi: 10.1016/j.ejso.2012.07.120. Epub 2012 Aug 9.</citation>
    <PMID>22878060</PMID>
  </reference>
  <reference>
    <citation>Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, Beijnen JH, Verwaal VJ. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015 Feb 1;479(1):23-7. doi: 10.1016/j.ijpharm.2014.12.025. Epub 2014 Dec 20.</citation>
    <PMID>25535649</PMID>
  </reference>
  <reference>
    <citation>Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20;25(30):4779-86.</citation>
    <PMID>17947725</PMID>
  </reference>
  <reference>
    <citation>Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM. Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers. Am J Obstet Gynecol. 2013 Jun;208(6):501.e1-7. doi: 10.1016/j.ajog.2013.03.012. Epub 2013 Mar 15.</citation>
    <PMID>23507546</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Bradley Switzer</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Appendiceal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

